Actively Recruiting
Evaluating New Diagnostic Tests for Tuberculosis in Children Aged 2 Months to 14 Years in Bolivia Using Blood and Lung Imaging Methods
Led by Tulane University · Updated on 2026-10-13
1220
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating new ways to diagnose tuberculosis TB in children in Bolivia, particularly addressing challenges in detecting TB in young children due to limited accuracy and availability of current tests. The study focuses on a novel CRISPR-mediated blood test CRISPR-TB that detects TB DNA fragments in the blood, aiming to improve detection especially in children with confirmed, unconfirmed, or unlikely TB. The research also explores combining blood test results with lung imaging techniques analyzed by artificial intelligence to enhance TB diagnosis. The study will enroll children aged 2 months to 14 years who are suspected of having TB based on respiratory symptoms and Bolivian health guidelines. Participants include those with confirmed TB, unconfirmed TB, unlikely TB, and well children without symptoms. The study involves multiple diagnostic tests, including blood tests, chest X-rays, lung ultrasounds, and specimen collections like sputum or gastric aspirate for culture and PCR analysis. Imaging data will be analyzed using advanced machine learning tools to correlate with blood test results. Participants will undergo initial evaluations before any TB treatment, including clinical exams, blood and respiratory sample collections, and imaging. Children diagnosed with TB will have follow-up assessments at 1 week, 2 weeks, and 2 months during treatment to monitor disease markers and response. Well children controls will have a single evaluation. The main outcome measured is the level of TB DNA in the blood at baseline and after treatment, along with imaging scores. The study aims to validate these diagnostic tools to better detect pediatric TB in resource-limited settings, with participation expected to last up to two months for treated children.
CONDITIONS
Brief Title
Diagnostic Innovations for Pediatric Tuberculosis in Bolivia
Research Team
R
Richard Oberhelman, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here